

10/574,649

=> d his

(FILE 'HOME' ENTERED AT 20:26:35 ON 12 APR 2009)

FILE 'CAPLUS' ENTERED AT 20:28:28 ON 12 APR 2009

L1 1 S 142:430156/DN
SELECT RN L1 1-

FILE 'REGISTRY' ENTERED AT 20:29:00 ON 12 APR 2009

L2 257 S E1-257
L3 200 S E258-457
L4 457 S L2 OR L3
L5 130 S 6-7/SZ AND L3
L6 110 S L5 AND NRS>1
L7 6 S 7-TRIFLUORO? AND L6
L8 327769 S 6-7/SZ
L9 121178 S L8 AND NRS=2
L10 16378 S 937.72.12/RID
L11 4460 S L9 AND L10
L12 114 S L11 AND 7-TRIFLUORO?
L13 26 S L12 AND ACETYL
L14 11 S L13 AND ACID
L15 2851365 S ETHYL ESTER
L16 129492 S 1-METHYLETHYL ESTER
L17 736 S L11 AND L15
L18 136 S L11 AND L16
L19 736 S L17 OR L18
L20 718 S L19 AND ACID

FILE 'CAPLUS' ENTERED AT 20:38:34 ON 12 APR 2009

FILE 'REGISTRY' ENTERED AT 20:42:11 ON 12 APR 2009

L21 234 S L20 AND TRIFLUORO?
L22 38 S L20 AND BROMO
L23 108 S L20 AND METHOXY
L24 111 S L20 AND CHLORO
L25 353 S L21 OR L22 OR L23 OR L24
L26 141 S L25 AND BIS



FILE 'CAPLUS' ENTERED AT 20:43:20 ON 12 APR 2009

L27 4 S L26

=> d ibib abs hitstr total

L27 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:1454729 CAPLUS
 DOCUMENT NUMBER: 148:79309
 TITLE: Preparation of benzazepinone amino acids as sodium channel blockers
 INVENTOR(S): Hoyt, Scott B.; London, Clare; Ok, Dong; Parsons, William H.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 114pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2007145922 | A2 | 20071221 | WO 2007-US13202 | 20070605 |
| WO 2007145922 | A3 | 20080821 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | |
| AU 2007258675 | A1 | 20071221 | AU 2007-258675 | 20070605 |
| CA 2652669 | A1 | 20071221 | CA 2007-2652669 | 20070605 |
| EP 2032539 | A2 | 20090311 | EP 2007-795744 | 20070605 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | |
| PRIORITY APPLN. INFO.: | | | US 2006-812402P | P 20060609 |
| | | | WO 2007-US13202 | W 20070605 |
| OTHER SOURCE(S): | MARPAT 148:79309 | | | |
| GI | | | | |



- AB Benzazepinone compds. I, wherein R1 is H, halogen, CN, alkyl, O-alkyl; Y is O, H2; R2 is H, alkyl, alkenyl, alkynyl, alkoxy-alkyl, cycloalkyl-alkyl; R3 is H, alkyl; R4 is alkyl, O-alkyl, cycloalkyl-alkyl, (CH2)n-aryl, (CH2)n-heteroaryl; R5 is (CH2)n-aryl, (CH2)n-heteroaryl; n is 0-2; R6 is H, halogen, were prepared and tested as sodium channel blockers. Thus, benzazepinone amino acid II was prepared and tested in vitro and in rats as sodium channel blocker. Pharmaceutical compns. comprise an effective amount of the instant compds., either alone, or in combination with one or more other therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritus, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compds., and a pharmaceutically acceptable carrier. The compds. described in this invention displayed sodium channel blocking activity of from about < 0.1 μ M to about < 50 μ M in the in vitro assays. It is advantageous that the compds. display sodium channel blocking activity of < 0.1 μ M in the in vitro assays.
- IT 960206-53-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzazepinone amino acids as sodium channel blockers)
- RN 960206-53-5 CAPLUS
- CN Carbamic acid, N-[(1R)-1-[[2,5-bis(trifluoromethyl)phenyl]methyl]-2-oxo-2-[[[(3R)-2,3,4,5-tetrahydro-1-(1-methylethyl)-2-oxo-1H-1-benzazepin-3-yl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10/574,649



L27 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:11309 CAPLUS

DOCUMENT NUMBER: 144:108328

TITLE: Preparation of benzo[blazepines and related compounds as inhibitors of cholesterol ester transfer protein for treating dyslipidemia

INVENTOR(S): Chen, Xinchao; Cioffi, Christopher Lawrence; Dinn, Sean Richard; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Herr, Robert Jason; Mantlo, Nathan Bryan; De la Nava, Eva Maria Martin; Mateo-Herranz, Ana Isabel; Parthasarathy, Saravanan; Wang, Xiaodong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006002342 | A1 | 20060105 | WO 2005-US22389 | 20050623 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2005267436 | A1 | 20060202 | AU 2005-267436 | 20050622 |
| AU 2005258241 | A1 | 20060105 | AU 2005-258241 | 20050623 |
| CA 2570673 | A1 | 20060105 | CA 2005-2570673 | 20050623 |
| EP 1761522 | A1 | 20070314 | EP 2005-763328 | 20050623 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| CN 1972932 | A | 20070530 | CN 2005-80020685 | 20050623 |
| JP 2008504277 | T | 20080214 | JP 2007-518296 | 20050623 |
| BR 2005012516 | A | 20080311 | BR 2005-12516 | 20050623 |
| IN 2006KN03401 | A | 20070615 | IN 2006-KN3401 | 20061117 |
| US 20070244095 | A1 | 20071018 | US 2006-570542 | 20061213 |
| MX 2006014706 | A | 20070312 | MX 2006-14706 | 20061214 |
| KR 2007031950 | A | 20070320 | KR 2006-727076 | 20061222 |
| KR 859223 | B1 | 20080918 | | |
| NO 2007000470 | A | 20070326 | NO 2007-470 | 20070124 |
| PRIORITY APPLN. INFO.: | | | US 2004-582708P | P 20040624 |
| | | | US 2004-627241P | P 20041112 |
| | | | US 2005-664862P | P 20050324 |
| | | | WO 2005-US22389 | W 20050623 |

OTHER SOURCE(S): CASREACT 144:108328; MARPAT 144:108328

GI




- AB Benzo[b]azepines and related compds. (shown as I; variables defined below; e.g. [3,5-bis(trifluoromethyl)benzyl] [(S)-1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl] (2-methyl-2H-tetrazol-5-yl)amine (shown as II)) and their pharmaceutical compns. and methods of use are disclosed. Although the methods of preparation are not claimed, preps. and/or characterization data for .apprx.200 examples of I are included. For example, II was prepared in 19 steps (>99, 95, 99, 92, >99, 96, 83, 87, 80, 63, 76, 85, >99, 98, >99, >99, 95 and 70% yields, resp.) starting with preparation of Me 2-nitro-4-trifluoromethylbenzoate from the acid. For I: n = 0-3; m = 0-3; p is 1 or 2; q is 0-4; Y is a bond, C:O, or S(O)t; wherein t = 0-2; R1 = hydroxy, C1-C6 alkyl, aryl, C2-C6 alkenyl, C1-C6 haloalkyl, et al.; each R2 is bound only to a C atom and is H, hydroxy, halogen, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, et al.; R3a and R3b = H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, and C1-C6 haloalkyl; R4 = -NR4aR4b wherein R4a is a heterocyclic, C1-C6 alkylheterocyclic, or C2-C6 alkenylheterocyclic group; and R4b = C1-C6 alkylaryl, C2-C6 alkenylaryl, C2-C6 alkynylaryl, C1-C6 alkylheterocyclic, C2-C6 alkenylheterocyclic, C1-C6 alkylcycloalkyl, et al.; R5 = H, hydroxy, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, aryloxy, et al.; R6 = H, C1-C6 alkyl, C2-C6 alkenyl, hydroxy, COR7, C1-C6 alkoxy, aryloxy, -OC2-C6 alkenyl, -OC1-C6 haloalkyl, C1-C6 alkylNR7R8, C3-C8 cycloalkyl, heterocyclic, aryl, C1-C6 alkyl-O-C(O)NR7R8, C1-C6 alkyl-NR7C(O)NR7R8 and C1-C6 alkylcycloalkyl; addnl. details including provisos are given in the claims. The ability of 37 examples of I to elevate HDL cholesterol levels was determined
- IT 851045-84-6P 872624-50-5P, Isopropyl 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-bromo-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate 872624-63-0P, (S)-tert-Butyl 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate 872624-64-1P, (S)-tert-Butyl 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-7-methyl-8-

trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate
 872625-01-9P, (S)-5-[[[3,5-Bis(trifluoromethyl)benzyl]amino]-7-ethyl-8-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid tert-butyl ester 872625-02-0P,
 (S)-5-[[[3,5-Bis(trifluoromethyl)benzyl](cyanoamino)-7-ethyl-8-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid tert-butyl ester 872625-06-4P, Isopropyl
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-8-chloro-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate 872625-12-2P, Isopropyl
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-oxobutyl)amino]-8-chloro-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate 872625-15-5P,
 Isopropyl 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-9-methyl-8-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylate 872625-66-6P, (S)-5-[[[3,5-Bis(trifluoromethyl)phenyl]methyl](3-oxobutyl)amino]-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzo[b]azepines and related compds. as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)


RN 851045-84-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 872624-50-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-bromo-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 872624-63-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-7-
 methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 872624-64-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-2,3,4,5-tetrahydro-
 7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 872625-01-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-ethyl-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 872625-02-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-7-ethyl-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 872625-06-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 872625-12-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](1,3-dioxobutyl)amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 872625-15-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,

5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-2,3,4,5-tetrahydro-9-methyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 872625-66-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,

5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-2,3,4,5-tetrahydro-7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)-(CA INDEX NAME)

Absolute stereochemistry.

10/574,649



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:371225 CAPLUS

DOCUMENT NUMBER: 142:430156

TITLE: Preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia

INVENTOR(S): Cao, Guoqing; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Gernert, Douglas Linn; Cioffi, Christopher Lawrence; Herr, Robert Jason; Mantlo, Nathan Bryan; Martin De La Nava, Eva Maria; Mateo Herranz, Ana Isabel; Mayhugh, Daniel Ray; Wang, Xiaodong

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|--|------------------|------------|
| WO 2005037796 | A1 | 20050428 | WO 2004-US30907 | 20041007 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004282101 | A1 | 20050428 | AU 2004-282101 | 20041007 |
| CA 2537942 | A1 | 20050428 | CA 2004-2537942 | 20041007 |
| EP 1670768 | A1 | 20060621 | EP 2004-793889 | 20041007 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004014186 | A | 20061031 | BR 2004-14186 | 20041007 |
| CN 1863778 | A | 20061115 | CN 2004-80029540 | 20041007 |
| JP 2007508301 | T | 20070405 | JP 2006-533949 | 20041007 |
| IN 2006KN00372 | A | 20070316 | IN 2006-KN372 | 20060220 |
| US 20070254869 | A1 | 20071101 | US 2006-574649 | 20060330 |
| KR 2006085675 | A | 20060727 | KR 2006-706837 | 20060407 |
| MX 2006003927 | A | 20080207 | MX 2006-3927 | 20060407 |
| NO 2006002074 | A | 20060508 | NO 2006-2074 | 20060508 |
| PRIORITY APPLN. INFO.: | | | US 2003-509736P | P 20031008 |
| | | | WO 2004-US30907 | W 20041007 |
| OTHER SOURCE(S): | | CASREACT 142:430156; MARPAT 142:430156 | | |
| GI | | | | |



AB Title compds. I [n, m, q = 0-3; p = 1-2; R1 = OH, alkyl, aryl, etc.; R2 = H, OH, halo, etc.; R3 = H; R4 = (un)substituted amino; R5 = H, OH, halo, etc.; R6 = allyl alc., alkoxy, etc.] are prepared For instance, 5-[acetyl(3,5-bis(trifluoromethyl)benzyl)amino]-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid iso-Pr ester (II) is prepared in 8 steps from 2-aminobenzoic acid Me ester, Et 4-bromobutyrate and 3,5-bis(trifluoromethyl)benzylamine. II has an IC50 of 293 nM for cholesterol ester transfer protein (CETP). I are useful for treating atherosclerosis and its sequelae.


IT 1044022-86-7

RL: PRPH (Prophetic)

(Preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 1044022-86-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(2-ethylhydrazinyl)-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



IT 851044-03-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851044-03-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 851043-54-4P 851043-55-5P 851043-97-5P

851043-98-6P 851044-04-7P 851044-11-6P

851044-12-7P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851043-54-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851043-55-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 851043-97-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 851043-98-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851044-04-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester, (5S)- (CA INDEX NAME)


Absolute stereochemistry.

10/574,649




RN 851044-11-6 CAPLUS
CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1,1-dimethylethyl)amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5R)- (CA INDEX
NAME)

Absolute stereochemistry.




RN 851044-12-7 CAPLUS
CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(1,1-dimethylethyl)amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester, (5S)- (CA INDEX
NAME)


Absolute stereochemistry.




IT 851042-69-8P 851042-71-2P 851042-92-7P
 851043-04-4P 851043-05-5P 851043-08-8P
 851043-13-5P 851043-24-8P 851043-34-0P
 851043-39-5P 851043-46-4P 851043-50-0P
 851043-95-3P 851043-96-4P 851044-00-3P
 851044-02-5P 851044-05-8P 851044-07-0P
 851044-09-2P 851044-10-5P 851044-23-0P
 851044-31-0P 851044-32-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzazepines as inhibitors of cholesterol ester transfer
 protein for treating dyslipidemia)
 RN 851042-69-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-71-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-92-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-04-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-05-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-08-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-amino-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-13-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-24-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(methylthio)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-34-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-39-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-8-fluoro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-46-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-bromo-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-50-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-bromo-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-95-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-96-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-00-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-02-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-05-8 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-07-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethenyl-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-09-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-bromo-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851044-10-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-methyl-8-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-23-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-bromo-2,3,4,5-
 tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-31-0 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851044-32-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 851042-67-6P 851042-68-7P 851042-70-1P
 851042-72-3P 851042-73-4P 851042-91-6P
 851042-93-8P 851042-94-9P 851042-95-0P
 851042-98-3P 851042-99-4P 851043-00-0P
 851043-01-1P 851043-02-2P 851043-03-3P
 851043-07-7P 851043-09-9P 851043-10-2P
 851043-14-6P 851043-15-7P 851043-16-8P
 851043-17-9P 851043-18-0P 851043-21-5P
 851043-23-7P 851043-25-9P 851043-27-1P
 851043-28-2P 851043-29-3P 851043-30-6P
 851043-31-7P 851043-32-8P 851043-33-9P
 851043-35-1P 851043-36-2P 851043-37-3P
 851043-38-4P 851043-40-8P 851043-41-9P
 851043-43-1P 851043-44-2P 851043-45-3P
 851043-47-5P 851043-48-6P 851043-49-7P
 851043-51-1P 851043-52-2P 851043-53-3P
 851043-56-6P 851043-57-7P 851043-58-8P
 851043-59-9P 851043-61-3P 851043-63-5P
 851043-65-7P 851043-67-9P 851043-69-1P
 851043-85-1P 851043-99-7P 851044-01-4P
 851044-06-9P 851044-08-1P 851044-16-1P
 851044-17-2P 851044-19-4P 851044-20-7P
 851044-22-9P 851044-24-1P 851044-25-2P
 851044-26-3P 851044-27-4P 851044-33-2P
 851044-34-3P 851044-38-7P 851044-47-8P
 851044-55-8P 851044-77-4P 851044-79-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851042-67-6 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-68-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-70-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-72-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-(trifluoromethoxy)-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-73-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851042-91-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-93-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-94-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-[(methylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-95-0 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
7-(acetyl)amino)-5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-98-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethenyl-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851042-99-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
7-acetyl-5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-00-0 CAPLUS
 CN 1H-1-Benzazepine-1,7-dicarboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 7-methyl 1-(1-methylethyl) ester (CA INDEX NAME)




RN 851043-01-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-formyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-02-2 CAPLUS
 CN 1H-1-Benzazepine-1,7-dicarboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 1-(1-methylethyl) ester (CA INDEX NAME)




RN 851043-03-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-07-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-cyano-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-09-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-[(methylsulfonyl)amino]-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-10-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 8-(acetylamino)-5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-14-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-ethenyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-15-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-ethyl-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-16-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(dimethylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-17-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(diethylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-18-0 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(hydroxymethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-21-5 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-(ethylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-23-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-25-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-(methylsulfonyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-27-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-hydroxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-28-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-bromo-2,3,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851043-29-3 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851043-30-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-7-cyano-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-31-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7,8-dichloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-32-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-7-
 (dimethylamino)-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-33-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-7-methoxy-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-35-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-chloro-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-36-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-amino-2,3,4,5-
 tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-37-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
2,3,4,5-tetrahydro-8-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-38-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7,8-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-40-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-fluoro-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-41-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 7,8-dimethoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-43-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-44-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-45-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-47-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-(trifluoromethoxy)-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-48-6 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-amino-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-49-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-(dimethylamino)-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-51-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-amino-2,3,4,5-
tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-52-2 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-9-(dimethylamino)-
2,3,4,5-tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-53-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7,9-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-56-6 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-57-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-58-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 851043-59-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




RN 851043-61-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](1-oxopropyl)amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-63-5 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2,2,2-trifluoroacetyl)amino]-8-
chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-65-7 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](ethoxycarbonyl)amino]-8-chloro-
2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851043-67-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(1-
 methylethoxy)carbonyl]amino]-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl
 ester (CA INDEX NAME)




RN 851043-69-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl][(ethylamino)carbonyl]amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-85-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(2,4-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851043-99-7 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-01-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-chloro-2,3,4,5-
 tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-06-9 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-(dimethylamino)-
 2,3,4,5-tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX
 NAME)




RN 851044-08-1 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-7-ethyl-2,3,4,5-
tetrahydro-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-16-1 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7,9-dimethyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-17-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6-fluoro-2,3,4,5-
 tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-19-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl)methyl]formylamino]-8-chloro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-20-7 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]ethylamino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-22-9 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
6-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-24-1 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-25-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 8,9-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-26-3 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6-fluoro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-27-4 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
9-methyl-8-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 851044-33-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](1-oxopropyl)amino]-8-chloro-
 2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-34-3 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](3-methyl-1-oxobutyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851044-38-7 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methoxyacetyl)amino]-8-
 chloro-2,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 851044-47-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl([3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 2,2,2-trifluoro-1-methylethyl ester (CA INDEX NAME)




RN 851044-55-8 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, S-(1-methylethyl) ester (CA INDEX NAME)




RN 851044-77-4 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 851044-79-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methylsulfonyl)amino]-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




IT 851045-84-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzazepines as inhibitors of cholesterol ester transfer
protein for treating dyslipidemia)

RN 851045-84-6 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




IT 851045-13-1P 851045-25-5P 851045-37-9P
851045-43-7P 851045-48-2P 851045-56-2P
851045-60-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepines as inhibitors of cholesterol ester transfer protein for treating dyslipidemia)

RN 851045-13-1 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methylamino]-7-bromo-8-chloro-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 851045-25-5 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,

5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3,4,5-tetrahydro-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-37-9 CAPLUS

CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-6-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-43-7 CAPLUS


CN 1H-1-Benzazepine-1-carboxylic acid,
5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-tetrahydro-9-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-48-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6-fluoro-2,3,4,5-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 851045-56-2 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-7-
 (trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851045-60-8 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-8-chloro-2,3,4,5-
 tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 1001387-85-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of benzazepines as inhibitors of cholesterol ester transfer
 protein for treating dyslipidemia)
 RN 1001387-85-4 CAPLUS
 CN 1H-1-Benzazepine-1-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
 9-methyl-7-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:380403 CAPLUS

DOCUMENT NUMBER: 135:5536

TITLE: Preparation of substituted 1-benzazepines and derivatives thereof as antibacterial agents

INVENTOR(S): Tomazic, Alenka; Huang, Liren; Tucker, Kenneth D.

PATENT ASSIGNEE(S): Antexpharma, Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2001035964 | A1 | 20010525 | WO 2000-US30576 | 20001107 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2391498 | A1 | 20010525 | CA 2000-2391498 | 20001107 |
| EP 1229913 | A1 | 20020814 | EP 2000-977008 | 20001107 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 6514965 | B1 | 20030204 | US 2000-706863 | 20001107 |
| JP 2003514022 | T | 20030415 | JP 2001-537956 | 20001107 |
| AU 784646 | B2 | 20060518 | AU 2001-14702 | 20001107 |
| MX 2002005070 | A | 20030925 | MX 2002-5070 | 20020517 |
| PRIORITY APPLN. INFO.: | | | US 1999-166167P | P 19991118 |
| | | | WO 2000-US30576 | W 20001107 |

OTHER SOURCE(S):

MARPAT 135:5536

GI



AB Title compds. (I) [wherein R1 = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, or Ar or (CH2)nAr, (CH2)mCOR, (CH2)nCN, (CH2)mC(Q)OR, CONR2, OR, SO2R, CONHNH, CH2OR, (CH2)nOAr, (CH2)mC(NH)NH2, or (CH2)nNHAr; R2 and R3 = independently H, halo, N3, CN, (un)substituted (cyclo)alkyl, alkenyl, alkynyl, or Ar or (CH2)nAr, (CH2)mNR2, (CH2)mNHAA, (CH2)mNC(O)R, (CH2)mCONHOR, (CH2)mCOOR, (CH2)mCONHAA, (CH2)mCONR2, or (CH2)nCONHAA; R4 and R5 = independently H, halo, NO2, CN, (un)substituted (cyclo)alkyl,

alkenyl, alkynyl, Ar, (CH₂)_nAr, primary or secondary amino, or NHC(O)R, QR, NHC(Q)NHCOOR, NHCQNHR, OCONR₂, COOR, or OSiR₃; R = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, Ar, or (CH₂)_nAr; Q = O or S; Z = O or S; m = 0-2; n = 1-3; Ar = (hetero)aryl or arylalkyl; Aa = CX(NH₂)CO₂H; X = a group that completes a natural or synthetic amino acid] and their compns. were prepared as antibacterial agents. For example, 7-methoxy-1-tetralone oxime (preparation given) was treated with P₂O₅ in MeSO₃H to provide 8-methoxy-2,3,4,5-tetrahydro-1H-1-benzazepine-2-one (73%). The benzazepine was stirred with di-Et pyrocarbonate in the presence of LDA in THF to give the 3-substituted product (34%), which was then alkylated with EtI in AcCN using Cs₂CO₃ to afford II (48%). In antibacterial activity testing by the broth dilution method, II inhibited growth of bacteria significantly.


IT 1100848-24-5

RL: PRPH (Prophetic)

(Preparation of substituted 1-benzazepines and derivatives thereof as antibacterial agents)

RN 1100848-24-5 CAPLUS

CN 3H-1-Benzazepine-3,3-dicarboxylic acid,
1-ethyl-1,2,4,5-tetrahydro-8-methoxy-2-oxo-7-phenyl-,
3,3-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT